Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neurilemmoma 1Neoplasm Metastasis 1Meningioma 1Carcinoma, Renal Cell 1

Interventions

Hydroxyurea 3Bevacizumab 3pembrolizumab 2Imatinib Mesylate 2Everolimus 2vistusertib 1vatalanib 1pasireotide 1fludarabine phosphate 1fludarabine 1arginyllysine 1antineoplaston AS 2-1 1antineoplaston A10 1aldesleukin 1Whole Body Imaging 1Verapamil 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Nivolumab 1Modafinil 1Magnetic Resonance Spectroscopy 1Ipilimumab 1HDAC-42 1Fentanyl 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningioma × HDAC-42 × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡